Physician profile
Mark Jonathan Smith
NPI 1063432284
$9,168.50
in general payments reported to CMS, 2019-2025
31 companies · $899 in 2025
The $899 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $1,227 · 2021: $1,415 · 2022: $1,778 · 2023: $1,286 · 2024: $1,458 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,630 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.46 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,361.40 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,012.92 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $930.84 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $916.07 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $601.43 | 2020-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $575.61 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $556.02 | 2019-2022 | |
| Allergan, INC. | $527.67 | 2019-2020 | |
| Lundbeck LLC | $441.63 | 2021-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $386.88 | 2019-2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $205.96 | 2022-2025 | Auvelity |
| Eisai INC. | $182.12 | 2020-2022 | |
| Alkermes, INC. | $159.09 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $151.69 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $144.54 | 2019-2024 | Austedo Xr, Uzedy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $139.11 | 2020-2023 | Belsomra |
| Corium, LLC | $118.90 | 2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $118.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $96.46 | 2019-2024 | Spravato |
| Neos Therapeutics, Lp | $87.77 | 2019-2020 | |
| Bausch Health US, LLC | $86.07 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $75.45 | 2019-2025 | Relexxii |
| Shire North American Group INC | $69.24 | 2019 | |
| Jazz Pharmaceuticals INC. | $58.75 | 2020 | |
| Almatica Pharma LLC | $38.42 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $33.85 | 2025 | Jornay Pm |
| Lilly USA, LLC | $27.18 | 2025 | Zepbound |
| Alfasigma USA, INC. | $21.28 | 2022 | |
| Tempus Ai, INC | $18.13 | 2024 | Tempus Pixel |
| Arbor Pharmaceuticals, INC. | $14.75 | 2019 | |
| Uswm, LLC | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.